Auauniversity

AUA2024: A Specialized Masterclass for Single-port Robot-Assisted Surgery Guests: Simone Crivellaro, MD and Ahmed Ghazi MD, MHPE Outline: Segment #1 Topic: The need for ongoing surgical education given the rise in introduction of new technologies in urology. Segment #2 Topic: Current status of Hands-on skills courses in Urology Segment #3 Topic: History of hands on courses offered at AUA Segment #4 Topic: Educational approach for surgical training Segment #5 Topic: Single-port masterclass at AUA a step in a new direction

Update Series (2024) Lesson 1: A Case-Based Discussion of Priapism Guidelines Now in its 43rd installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information or to subscribe to the AUA Update Series, please visit AUAnet.org/Update24

AUA2023 Take Home Messages Part 5 Take Home Messages: Take Home Messages: BPH/LUTS Speaker: Dr. Dean Elterman Take Home Messages: Imaging Speaker: Dr. Richard Matulewicz Take Home Messages: Robotic Surgery Speaker: Dr. Andrew Hung Take Home Messages: Surgical Education Speaker: Dr. Simone Thavaseelan

AUA2023 Take Home Messages Part 4 Take Home Messages: Increasing Representation in Urology Speaker: Dr Larissa Bresler Take Home Messages: Healthcare Disparities Speaker: Dr. Adam Murphy Take Home Messages: Transplantation Speaker: Dr. Jason Lee Take Home Messages: Female Urology/Incontinence Speaker: Dr. Yahir Santiago-Lastra

AUA2023 Take Home Messages Part 3 Take Home Messages: Infertility/Andrology Speaker: Dr. Joshua Halpern Take Home Messages: Sexual Dysfunction Speaker: Dr. Peter Tsambarlis Take Home Messages: Pediatrics Speaker: Dr. Kate Kraft Take Home Messages: Global Health/Humanitarian Speaker: Dr. Rajiv Singal

AUA2023 Take Home Messages Part 2 Take Home Messages: Basic Science (Benign) Speaker: Dr. Douglas Strand Take Home Messages: Reconstruction Speaker: Dr. Jessica DeLong Take Home Messages: Endourology/Stones Speaker: Dr. Noah Canvasser Take Home Messages: Infection/Inflammation Speaker: Dr. Chris Doiron

AUA2023 Take Home Messages Part 1 Take Home Messages: Basic Science (Malignant) Speaker: Dr. Douglas Scherr Take Home Messages: Kidney Cancer Speaker: Dr. Amy Luckenbaugh Take Home Messages: Bladder Cancer Speaker: Dr. Jennifer Taylor Take Home Messages: Prostate Cancer Speaker: Dr. Samuel Washington

PARPi: Management of Adverse Events (2024) CME Available: https://auau.auanet.org/node/39609 Release Date: January, 2024 Expiration Date: January, 2025 LEARNING OBJECTIVES: 1. Identify approved PARPi for prostate cancer and patients who may benefit from PARPi based therapy. 2. Evaluate available clinical safety and efficacy data for PARPi. 3. Describe indications and contraindications for PARPi in patients with advanced prostate cancer. 4. Identify how to manage adverse events that patients may experience while taking a PARPi. ACKNOWLEDGEMENTS: This educational activity is supported by an independent educational grant from: Pfizer, Inc.

AUA2023 Journal of Urology Lecture: Surgery Harms Surgeons. What can we do? Speaker: Dr. Kevin Turner

AUA2023 Ramon Guiteras Lecture: The Complicated Decisions Required to Eliminate Never Events Speaker: Dr Louis Kavoussi, Smith Institute For Urology.

AUA2023 John Duckett Memorial Lecture: Innovation by Necessity: Improving Urodynamics for Children with Spina Bifida Speaker: Dr. Johnathan Routh, Chief of Children's Surgery, Duke University School of Medicine.

AUA2023 John K. Lattimer Lecture: Innovation in Urology: From a Seminal “Why” to a Functional “How” Speaker: Dr. Ralph Clayman, Distinguished Professor / Endowed Chair in Endourology, University of California, Irvine.

The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer: Adjuvant Therapies for High-Risk Non-Metastatic Kidney Cancer CME Available: https://auau.auanet.org/node/39542 Release Date: December, 2023 Expiration Date: December, 2024 LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Identify the rationale behind using adjuvant therapies in high-risk non-metastatic kidney cancer and the goals of adjuvant treatment. 2. Describe the adjuvant therapies that have been investigated to date for high-risk non-metastatic kidney cancer, including targeted therapies, immunotherapies, and combination approaches. 3. Discuss the challenges and limitations associated with adjuvant therapy trials in high-risk non-metastatic kidney cancer, such as patient selection, trial design, and long-term follow-up. ACKNOWLEDGEMENTS: Support provided by independent educational grants from:  AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC  Lantheus Medic

The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer: The Latest Breakthroughs in Immunotherapy for GU Cancers CME Available: https://auau.auanet.org/node/39543 Release Date: December, 2023 Expiration Date: December, 2024 LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Identify the newest immunotherapy drugs approved for prostate, bladder, and kidney cancer, including immune checkpoint inhibitors and other novel immunotherapies. 2. Discuss the clinical evidence supporting the use of these immunotherapy drugs in prostate, bladder, and kidney cancer, including data from pivotal clinical trials, response rates, and survival outcomes. 3. Evaluate the safety profile and potential immune-related adverse events associated with the newest immunotherapy drugs in GU cancers. ACKNOWLEDGEMENTS: Support provided by independent educational grants from:  AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC  Lantheus Medical Imaging Merc

The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer: Germline Testing and Novel Approaches to Targeting Genetic Mutations in Prostate Cancer CME Available: auau.auanet.org/node/39487 Release Date: December, 2023 Expiration Date: December, 2024 LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to: 1. Identify the indications for germline testing in prostate cancer patients. 2. Explain how germline testing is used to identify genetic mutations in genitourinary (GU) cancers, specifically focusing on prostate cancer. 3. Analyze the potential advantages and challenges associated with using germline testing and targeted therapies in the management of prostate cancer. ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Astellas and Pfizer, Inc AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc.

The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer: Novel Imaging for Genitourinary Cancers - Diagnostics and Theranostics CME Available: https://auau.auanet.org/node/39411 Release Date: December, 2023 Expiration Date: December, 2024 LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to: 1. Review the latest clinical trials investigating the use of PET imaging agents in prostate, kidney, and urothelial cancer, including their diagnostic accuracy and impact on patient management. 2. Discuss the available PET imaging agents for prostate cancer, with a specific focus on PSMA (Prostate-Specific Membrane Antigen) PET imaging, including its mechanism of action and its potential for detection of primary tumors, lymph node metastases, and distant metastases. 3. Discuss the benefits of incorporating PET imaging, including PSMA PET, in guiding treatment decisions for GU cancers, such as its impact on treatment selection, treatment response assessment, and the potential

The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer: Early Detection of Prostate Cancer: AUA/SUO Guideline (2023) CME Available: https://auau.auanet.org/node/39410 Release Date: December, 2023 Expiration Date: December, 2024 LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to: 1. Discuss the potential benefits, limitations, and controversies associated with prostate cancer screening. 2. Summarize the key recommendations provided in the AUA/SUO Guideline regarding early detection strategies for prostate cancer. 3. Analyze the implications of the AUA/SUO Guideline on clinical practice, shared decision-making, and patient counseling regarding early detection of prostate cancer. ACKNOWLEDGEMENTS: Support provided by independent educational grants from:  Astellas and Pfizer AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC  Lantheus Medical Imaging Merck & Co., Inc.

The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer: Treatment Paradigms for Intermediate and High-Risk Non-Muscle Invasive Bladder Cancer CME Available: https://auau.auanet.org/node/39374 Release Date: December, 2023 Expiration Date: December, 2024 LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Describe the importance of individualized treatment decision-making and shared decision-making in the management of intermediate and high-risk NMIBC. 2. Discuss the challenges associated with BCG shortage and its impact on patient care and treatment decisions. 3. Evaluate alternative intravesical therapies for NMIBC, such as chemotherapeutic agents (e.g., mitomycin C, gemcitabine), novel immunotherapies (e.g., intravesical pembrolizumab), and clinical trials. ACKNOWLEDGEMENTS: Support provided by independent educational grants from:  AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC  Lantheus Medical Imaging Merck & Co., In

PARPi: Genetic Testing in Advanced Prostate Cancer - When and Who to Test (2023) CME Available: https://auau.auanet.org/node/39603 Release Date: December, 2023 Expiration Date: December, 2024 LEARNING OBJECTIVES: At the conclusion of this activity, the learner will be able to: 1. Review recommended criteria for genetic testing of prostate cancer patients, currently available gene panels, and options for testing these men. 2. Explain the importance of testing for germline and somatic mutations and their implications for utilizing PARPi. 3. Describe work flows for genetic testing and utilization of genetic counselors. 4. Describe the genetic counseling process and the importance of pre-test counseling to discuss the benefits, limitations, and potential implications of germline testing for patients and their families. ACKNOWLEDGEMENT This educational activity is supported by an independent educational grant from Pfizer, Inc.

Infectious Complications Following Prostate Biopsy: Strategies for Reducing Infections and Reducing Health Care Costs CME Available: https://auau.auanet.org/node/39485 Release Date: December, 2023 Expiration Date: December, 2024 LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to: 1. Describe health care costs associated with prostate biopsy infections. 2. Identify the steps where modifications in technique can reduce the risk of complications. 3. Apply modified technique at various steps of the procedures to mitigate the risk of complications. ACKNOWLEDGEMENT Project Firstline is a national collaborative led by the U.S. Centers for Disease Control and Prevention (CDC) to provide infection control training and education to frontline health care workers and public health personnel. AMA has partnered with Project Firstline, as supported through Cooperative Agreement CDC-RFA-CK20-2003.  The American Urological Association is proud to collaborate with AMA and Project Firstline